Wynne H A, Rawlins M D
Wolfson Unit of Clinical Pharmacology, University of Newcastle upon Tyne, UK.
Eur J Clin Pharmacol. 1993;44(4):309-13. doi: 10.1007/BF00316464.
It is uncertain as to the extent which gastrointestinal (GI) haemorrhage related to NSAIDs is due to a local, topical effect or to an action related to systemic absorption. We hypothesised that, should systemic drug concentrations be of importance, plasma levels of NSAIDs might be higher in patients who had developed GI haemorrhage, from controls who had not. Ten patients with GI haemorrhage, who had ingested piroxicam (and no other NSAID), within the preceding 64 h, at the same dosage and on no new medication for the past 14 days, had blood taken at presentation for measurement of piroxicam concentrations. Plasma piroxicam concentrations were measured in 19 community dwelling controls, matched for age +/- 8 years, gender, daily piroxicam dosage, and time from last dose as their respective index case. All had been taking piroxicam for at least 3 months, and none had experienced GI adverse effects. Median plasma piroxicam concentrations in patients at 8.27 micrograms/l, was higher than in controls at 5.06 micrograms/l. These results suggest that a systemic component, at least with piroxicam, may play a significant (though not necessarily exclusive) role in causing major gastrointestinal haemorrhage.
与非甾体抗炎药(NSAIDs)相关的胃肠道(GI)出血在多大程度上是由于局部、局部效应还是与全身吸收相关的作用尚不确定。我们假设,如果全身药物浓度很重要,那么发生GI出血的患者的NSAIDs血浆水平可能高于未发生出血的对照组患者。10例在过去64小时内摄入吡罗昔康(且未摄入其他NSAIDs)、剂量相同且在过去14天内未服用新药的GI出血患者,在就诊时采血以测量吡罗昔康浓度。在19名社区居住的对照组中测量了血浆吡罗昔康浓度,这些对照组在年龄(±8岁)、性别、每日吡罗昔康剂量以及距上次服药时间方面与各自的索引病例相匹配。所有对照组均服用吡罗昔康至少3个月,且均未出现GI不良反应。患者的血浆吡罗昔康浓度中位数为8.27微克/升,高于对照组的5.06微克/升。这些结果表明,至少对于吡罗昔康而言,全身因素可能在导致严重胃肠道出血中起重要作用(尽管不一定是唯一作用)。